Answers are grounded in this paper and cite their sources.
Systematic review reveals high metabolic syndrome prevalence in epilepsy patients, indicating the need for early risk factor monitoring.
OBJECTIVE: This study aimed to standardize the global prevalence of metabolic syndrome (MetS) in patients with epilepsy. METHODS: Several databases including PubMed, Scopus, Web of Science, Embase, Science Direct, and Google Scholar were thoroughly searched. Studies up to 2025 on MetS prevalence in people with epilepsy were included. The search covered cross-sectional, cohort, and case-control studies in English that reported MetS prevalence in this group. Statistical analysis was performed using Comprehensive Meta-Analysis software (Version 2). The I² statistic was used to assess heterogeneity across studies, and the random-effects model was applied for data analysis. CONCLUSION: The results highlighted a high prevalence of MetS among patients with epilepsy. Therefore, healthcare professionals should not only focus on epilepsy but also regularly monitor risk factors associated with MetS and identify them early in patients with epilepsy.
No takes yet. Share an insight, caveat, or question.
Heidarian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: